cancer_therapy

Shanghai – September 26, 2026 -- A retrospective analysis of 102 multiple myeloma patients treated with IASO Bio's FUCASO CAR-T therapy found that patients maintaining sustained minimal residual disease (MRD) negativity showed a median CAR-T cell persistence of 463 days, compared with 272 days in patients who experienced MRD conversion — a gap of roughly 191 days. The data, drawn from the pivotal FUMANBA-1 registration study, were presented as a poster (Abstract No. PA-469) at the 2026 International Myeloma Society Annual Meeting.

Irvine, California – September 11, 2026 -- PeproMene Bio, Inc. reported that seven of nine patients (80%) treated with its BAFF-R-targeted CAR-T therapy PMB-CT01 achieved complete remission in a Phase 1 trial, with results now published in The Lancet.

All complete responses remained relapse-free at data cutoff, with the longest sustained remission reaching 35 months

Four of six patients who had previously progressed after conventional CD19-directed CAR-T therapy also achieved complete response under the new BAFF-R approach, described in the study as "CAR after CAR" treatment. No relapses were observed among any of the seven complete responders as of the data cutoff.